Search | IOVS | ARVO Journals

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial

Carl J Danzig; Hugh Lin; Pascal Guibord; David Silverman; Carlos Quezada Ruiz; Ivo Stoilov; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1160. doi:

ARVO Annual Meeting Abstract July 2018

Five-year progression of newly diagnosed untreated diabetic retinopathy in a real-world setting from a large US claims database

Andrew A Moshfeghi; Avanti Ghanekar; Ibrahim Abbass; Daniel Sheinson; Carlos Quezada-Ruiz; Vincent Garmo

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2599. doi:

ARVO Annual Meeting Abstract June 2017

Ranibizumab versus verteporfin photodynamic therapy for myopic choroidal neovascularization: Results from RADIANCE

Nathan Steinle; Avanti Ghanekar; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5920. doi:

ARVO Annual Meeting Abstract June 2017

Assessing the usability of the ranibizumab 0.5 mg prefilled syringe (PFS) by healthcare professionals in the US

Andrew N Antoszyk; Carl W Baker; Howard Cummings; Jorge Calzada; Joanna So; Carlos Quezada-Ruiz; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1953. doi:

ARVO Annual Meeting Abstract June 2017

Branch and central retinal vein occlusion: clinical pearls from trials of ranibizumab

Mimi Liu; David Eichenbaum; Sarah Taylor; Pin-wen Wang; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4624. doi:

ARVO Annual Meeting Abstract June 2017

Different characteristics predict good visual outcomes in patients with CRVO vs BRVO; hypertension is associated with good outcome in CRVO but not BRVO

Peter A Campochiaro; Raafay Sophie; Ann Clark; Na Lu; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4626. doi:

ARVO Annual Meeting Abstract September 2016

Pan-retinal photocoagulation for diabetic retinopathy: is it one and done?

Victor H Gonzalez; Pin-wen Wang; Carlos Quezada Ruiz; Anne E Fung

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6355. doi:

ARVO Annual Meeting Abstract September 2016

Differences in anti-vascular endothelial growth factor (anti-VEGF) injection frequency and costs for ranibizumab versus aflibercept in patients with diabetic macular edema (DME)

Carlos Quezada Ruiz; Yamina Rajput; Kathleen Wilson; Alice Huang; David M Smith; Helen Varker; Stephen S Johnston

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2101. doi:

ARVO Annual Meeting Abstract September 2016

Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: A 2-year US claims analysis

Szilard Kiss; Yamina Rajput; Carlos Quezada Ruiz; Kathleen Wilson; Alice Huang; David M Smith; Helen Varker; Stephen S Johnston

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3335. doi:

ARVO Annual Meeting Abstract September 2016

Prevalence of drusen and conversion to neovascular age-related macular degeneration in the HARBOR study fellow eyes

Caroline R Baumal; Carlos Quezada Ruiz; Shamika Gune; Pin-wen Wang; Anne E Fung

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4967. doi:

Advertisement